Dermatological adverse events under programmed cell death‐1 inhibitors as a prognostic marker in metastatic melanoma

Melanoma is widely treated with programmed cell death‐1 (PD‐1) inhibitors. As part of their anti‐tumor immunity effect, they increase the susceptibility to cutaneous immune‐related adverse events (cIRAE) among other autoimmune effects. To characterize the manifestations of cIRAE in melanoma patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Shreberk‐Hassidim, Rony, Aizenbud, Lilach, Lussheimer, Shalev, Thomaidou, Elena, Bdolah‐Abram, Tali, Merims, Sharon, Popovtzer, Aron, Maly, Alex, Lotem, Michal, Zlotogorski, Abraham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786241/
https://www.ncbi.nlm.nih.gov/pubmed/36190005
http://dx.doi.org/10.1111/dth.15747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786241/
https://www.ncbi.nlm.nih.gov/pubmed/36190005
http://dx.doi.org/10.1111/dth.15747

Ejemplares similares